Cargando…
Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers
BACKGROUND: Quantitative interstitial abnormalities (QIA) are an automated computed tomography (CT) finding of early parenchymal lung disease, associated with worse lung function, reduced exercise capacity, increased respiratory symptoms, and death. The metabolomic perturbations associated with QIA...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625195/ https://www.ncbi.nlm.nih.gov/pubmed/37925418 http://dx.doi.org/10.1186/s12931-023-02576-2 |
_version_ | 1785131078666682368 |
---|---|
author | Choi, Bina San José Estépar, Raúl Godbole, Suneeta Curtis, Jeffrey L. Wang, Jennifer M. San José Estépar, Rubén Rosas, Ivan O. Mayers, Jared R. Hobbs, Brian D. Hersh, Craig P. Ash, Samuel Y. Han, MeiLan K. Bowler, Russell P. Stringer, Kathleen A. Washko, George R. Labaki, Wassim W. |
author_facet | Choi, Bina San José Estépar, Raúl Godbole, Suneeta Curtis, Jeffrey L. Wang, Jennifer M. San José Estépar, Rubén Rosas, Ivan O. Mayers, Jared R. Hobbs, Brian D. Hersh, Craig P. Ash, Samuel Y. Han, MeiLan K. Bowler, Russell P. Stringer, Kathleen A. Washko, George R. Labaki, Wassim W. |
author_sort | Choi, Bina |
collection | PubMed |
description | BACKGROUND: Quantitative interstitial abnormalities (QIA) are an automated computed tomography (CT) finding of early parenchymal lung disease, associated with worse lung function, reduced exercise capacity, increased respiratory symptoms, and death. The metabolomic perturbations associated with QIA are not well known. We sought to identify plasma metabolites associated with QIA in smokers. We also sought to identify shared and differentiating metabolomics features between QIA and emphysema, another smoking-related advanced radiographic abnormality. METHODS: In 928 former and current smokers in the Genetic Epidemiology of COPD cohort, we measured QIA and emphysema using an automated local density histogram method and generated metabolite profiles from plasma samples using liquid chromatography–mass spectrometry (Metabolon). We assessed the associations between metabolite levels and QIA using multivariable linear regression models adjusted for age, sex, body mass index, smoking status, pack-years, and inhaled corticosteroid use, at a Benjamini–Hochberg False Discovery Rate p-value of ≤ 0.05. Using multinomial regression models adjusted for these covariates, we assessed the associations between metabolite levels and the following CT phenotypes: QIA-predominant, emphysema-predominant, combined-predominant, and neither- predominant. Pathway enrichment analyses were performed using MetaboAnalyst. RESULTS: We found 85 metabolites significantly associated with QIA, with overrepresentation of the nicotinate and nicotinamide, histidine, starch and sucrose, pyrimidine, phosphatidylcholine, lysophospholipid, and sphingomyelin pathways. These included metabolites involved in inflammation and immune response, extracellular matrix remodeling, surfactant, and muscle cachexia. There were 75 metabolites significantly different between QIA-predominant and emphysema-predominant phenotypes, with overrepresentation of the phosphatidylethanolamine, nicotinate and nicotinamide, aminoacyl-tRNA, arginine, proline, alanine, aspartate, and glutamate pathways. CONCLUSIONS: Metabolomic correlates may lend insight to the biologic perturbations and pathways that underlie clinically meaningful quantitative CT measurements like QIA in smokers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02576-2. |
format | Online Article Text |
id | pubmed-10625195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106251952023-11-05 Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers Choi, Bina San José Estépar, Raúl Godbole, Suneeta Curtis, Jeffrey L. Wang, Jennifer M. San José Estépar, Rubén Rosas, Ivan O. Mayers, Jared R. Hobbs, Brian D. Hersh, Craig P. Ash, Samuel Y. Han, MeiLan K. Bowler, Russell P. Stringer, Kathleen A. Washko, George R. Labaki, Wassim W. Respir Res Research BACKGROUND: Quantitative interstitial abnormalities (QIA) are an automated computed tomography (CT) finding of early parenchymal lung disease, associated with worse lung function, reduced exercise capacity, increased respiratory symptoms, and death. The metabolomic perturbations associated with QIA are not well known. We sought to identify plasma metabolites associated with QIA in smokers. We also sought to identify shared and differentiating metabolomics features between QIA and emphysema, another smoking-related advanced radiographic abnormality. METHODS: In 928 former and current smokers in the Genetic Epidemiology of COPD cohort, we measured QIA and emphysema using an automated local density histogram method and generated metabolite profiles from plasma samples using liquid chromatography–mass spectrometry (Metabolon). We assessed the associations between metabolite levels and QIA using multivariable linear regression models adjusted for age, sex, body mass index, smoking status, pack-years, and inhaled corticosteroid use, at a Benjamini–Hochberg False Discovery Rate p-value of ≤ 0.05. Using multinomial regression models adjusted for these covariates, we assessed the associations between metabolite levels and the following CT phenotypes: QIA-predominant, emphysema-predominant, combined-predominant, and neither- predominant. Pathway enrichment analyses were performed using MetaboAnalyst. RESULTS: We found 85 metabolites significantly associated with QIA, with overrepresentation of the nicotinate and nicotinamide, histidine, starch and sucrose, pyrimidine, phosphatidylcholine, lysophospholipid, and sphingomyelin pathways. These included metabolites involved in inflammation and immune response, extracellular matrix remodeling, surfactant, and muscle cachexia. There were 75 metabolites significantly different between QIA-predominant and emphysema-predominant phenotypes, with overrepresentation of the phosphatidylethanolamine, nicotinate and nicotinamide, aminoacyl-tRNA, arginine, proline, alanine, aspartate, and glutamate pathways. CONCLUSIONS: Metabolomic correlates may lend insight to the biologic perturbations and pathways that underlie clinically meaningful quantitative CT measurements like QIA in smokers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02576-2. BioMed Central 2023-11-04 2023 /pmc/articles/PMC10625195/ /pubmed/37925418 http://dx.doi.org/10.1186/s12931-023-02576-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Choi, Bina San José Estépar, Raúl Godbole, Suneeta Curtis, Jeffrey L. Wang, Jennifer M. San José Estépar, Rubén Rosas, Ivan O. Mayers, Jared R. Hobbs, Brian D. Hersh, Craig P. Ash, Samuel Y. Han, MeiLan K. Bowler, Russell P. Stringer, Kathleen A. Washko, George R. Labaki, Wassim W. Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title | Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title_full | Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title_fullStr | Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title_full_unstemmed | Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title_short | Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
title_sort | plasma metabolomics and quantitative interstitial abnormalities in ever-smokers |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625195/ https://www.ncbi.nlm.nih.gov/pubmed/37925418 http://dx.doi.org/10.1186/s12931-023-02576-2 |
work_keys_str_mv | AT choibina plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT sanjoseesteparraul plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT godbolesuneeta plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT curtisjeffreyl plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT wangjenniferm plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT sanjoseesteparruben plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT rosasivano plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT mayersjaredr plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT hobbsbriand plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT hershcraigp plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT ashsamuely plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT hanmeilank plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT bowlerrussellp plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT stringerkathleena plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT washkogeorger plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers AT labakiwassimw plasmametabolomicsandquantitativeinterstitialabnormalitiesineversmokers |